Regeneron completes acquisition of decibel therapeutics, adding promising gene therapy programs for hearing loss

Tarrytown, n.y., sept. 25, 2023 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that it has successfully completed its acquisition of decibel therapeutics, inc., strengthening the company's gene therapy and auditory programs.

REGN Ratings Summary

REGN Quant Ranking